Referencias

1. Luster M, Clarke SE, Dietlein M et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35:1941-59.
2. Kita T, Yokoyama K, Higuchi T et al. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med 2004; 18:345-9.
3. Lu L, Shan F, Li W, Lu H. Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer. Biomed Res Int 2016; 2016:4376720.
4. Sausville EA, Longo DL. Principles of Cancer Treatment. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill Education; 2015.
5. Ficha técnica Yoduro (131-I) de sodio GE Healthcare. GE Healthcare Bio-Sciences S. A. U. C/ Gobelas, 35-37, La Florida. 28023 Madrid. España. 07/2013.
6. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003; 13:265-71.
7. Dahllöf G, Borgström P, Lundell G et al. Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:420-3.
8. Pashnehsaz M, Takavar A, Izadyar S et al. Gastrointestinal side effects of the radioiodine therapy for the patients with differentiated thyroid carcinoma two days after prescription. World J Nucl Med 2016; 15:173-8.